CE Mark awarded to anti-CCP diagnostic kit

A diagnostic kit for rheumatoid arthritis has been given a CE Mark.

An anti-cyclic citrullinated peptides (anti-CCP) diagnostic kit for rheumatoid arthritis has been given the CE Mark of approval, Theradiag announced today (April 23rd).
This in-vitro test adds to the theranostic specialist's Fidis portfolio of equipment for auto-immunes diseases, with the technology expected to bring down the time and cost of analysis.
According to the company, this new method of uncovering anti-CCP antibodies provides a reliable detection of severe forms of rheumatoid arthritis at more rapid dosing and at a lower price than existing equipment.
It marks the third proprietary diagnostic kit of Theradiag to be offered a CE Mark this year, with the auto-immune diseases segment growing in 2012 and sparking a 17 per cent increase for its Fidis products.
"With this new addition to the Fidis range we position ourselves as testing and monitoring leaders in auto-immune and inflammatory diseases," said Michel Finance, chief executive of Theradiag.
A statement from the company revealed the auto-immune diseases segment made up 43 per cent of its total company sales last year.